Chronic Obstructive Pulmonary Disease (COPD) - Drug Pipeline Analysis

and Market Forecasts to 2016

The COPD Market is Forecast to Show Positive Growth until 2016

GlobalData estimated the Chronic Obstructive Pulmonary Disease (COPD) market to be

worth $7.2 billion in 2009 and projects it to grow at a compound annual growth rate
(CAGR) of 7.4% to reach $11.9 billion in 2016. The development of novel once-daily
inhaled therapies is expected to provide new treatment options for COPD patients
worldwide, and will play a major role in the expansion of the COPD market in the
coming years. A steady increase in the incidence rate, smoking population and in
injurious environmental factors in most countries has caused the COPD market to grow
significantly.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Chronic-Obstructive-
Pulmonary-Disease-COPD-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData has found that the COPD market has high levels of unmet need. Greater
unmet needs imply that the market is not well served by the current product options
with boundless scope available to new entrants to capture value from underserved
segments. Emerging therapies such as long-acting beta2 agonist (LABA)/inhaled
corticosteroid (ICS) combinations, long-acting muscarinic antagonists (LAMAs), and
LABA/LAMA, will emerge as potentially efficacious entrants over the coming years.
There is a need for drugs that can dramatically reduce exacerbation rates, slow or halt
the progression of COPD, and improve lung functions and the quality of life in COPD
patients. Overall, the market is likely to grow rapidly with the entry of these novel
combinational therapies and patient expectations are managed through more
efficacious products in near future.

GlobalData has found that Altana Pharma's Roflumilast, Almirall, S.A/Forest Lab's
aclidinium bromide, GlaxoSmithKline/Theravance's GW642444, which are in Phase III of
clinical development, are the most promising molecules in the COPD treatment pipeline
and will drive the COPD market in the near future.
Companies such as GlaxoSmithKline, Novartis AG, Pfizer Inc, AstraZeneca, Forest
Laboratories, Merck & Co, Boehringer Ingelheim and Sepracor, Inc have some of the
most technologically advanced products in their pipeline portfolios, and are therefore
expected to attract investors’ attention.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Chronic-Obstructive-
Pulmonary-Disease-COPD-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016
GlobalData has found that the COPD developmental pipeline is strong with over 130
molecules in various phases of clinical development. There are more than 67 first-in-
class molecules in different stages of clinical development. These molecules have
distinct advantages over the currently marketed players. Trials are being conducted on
novel mechanisms and combinational targeted therapies which may improve the
symptoms of COPD and prolong the lives of COPD patients. The launch of these
innovative products should lead to a decrease in the symptoms of exacerbations,
improvements in lung functions and improve patients’ quality of life.
Roflumilast, aclidinium bromide, glycopyrronium bromide, QAB149, GW642444 and
other combinational products are the most promising molecules currently in the
pipeline. These drugs are part of a new class of therapies that promises to add value to
the COPD market in the near future and may strongly compete with the current market
players on the basis of better efficacy and safety profiles.

GlobalData, the industry analysis specialist, has released its latest research, “Chronic
Obstructive Pulmonary Disease (COPD) - Drug Pipeline Analysis and Market Forecasts to
2016” which provides the key data, information and analysis on the COPD market. The
report provides a comprehensive overview of the annualized market data from 2001 to
2009, and forecast forward seven years to 2016. The research also includes market
characterization, opportunities, the unmet needs associated with COPD, competitive
assessment, the product profiles of the major marketed products and the promising
drugs in the pipeline, an overview of the discontinued projects, the implications for
future market competition, and the key players in the COPD market.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Chronic-Obstructive-
Pulmonary-Disease-COPD-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or visit our report store: http://www.globaldata.com/reportstore

Contact Information:
Rajesh Gunnam
rgunnam@globaldata.com
+914066166782